Search results for "CLINICAL TRIALS"

showing 10 items of 490 documents

Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report

2021

Allergen exposure chambers (AECs) can be used for controlled exposure to allergenic and non-allergenic airborne particles in an enclosed environment, in order to (i) characterize the pathological features of respiratory diseases and (ii) contribute to and accelerate the clinical development of pharmacological treatments and allergen immunotherapy for allergic disease of the respiratory tract (such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma). In the guidelines of the European Medicines Agency for the clinical development of products for allergen immunotherapy (AIT), the role of AECs in determining primary endpoints in dose-finding Phase II trials is emphasized. A…

Allergen immunotherapymedicine.medical_specialtyAllergyImmunologytechnical standardsmedicineImmunology and AllergyHumansallergen exposure chambersIntensive care medicineCOVID-19 ; allergen exposure chambers ; clinical trials ; Allergie ; technical standards ; allergen immunotherapyField exposureclinical trialsTask forcebusiness.industryCOVID-19Technical informationAllergic asthmaAllergensrespiratory systemmedicine.diseaseRhinitis AllergicAsthmaClinical trialDesensitization Immunologicallergen immunotherapyPollenALLERGEN EXPOSUREbusiness
researchProduct

MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

2015

Accepted Article

AllergyAllergyMedical InformaticSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOWORLD-HEALTH-ORGANIZATIONReviewComorbidityWeb BrowserHealth informatics:Medicina Clínica [Ciências Médicas]ARIA; ICT; MACVIA-LR; allergic rhinitis; asthma; clinical decision support system; conjunctivitis; visual analogue scalevisual analogue scaleQUALITY-OF-LIFEconjunctivitisMedicineImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSRhinitisClinical Trials as TopicCLIMATE-CHANGE[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyAllergenHealth PolicyDisease ManagementRANDOMIZED CONTROLLED-TRIAL3. Good healthCHRONIC RESPIRATORY-DISEASESclinical decision support systemINTEGRATED CARE PATHWAYS1107 ImmunologyVISUAL ANALOG SCALESPractice Guidelines as TopicMedical emergencyallergic rhinitiLife Sciences & BiomedicineHumanEUROPEAN INNOVATION PARTNERSHIPImmunologyClinical Decision-MakingSocio-culturaleReproducibility of Resultallergic rhinitis; ARIA; asthma; Information and communications technology; MACVIA-LR; Allergens; Biomarkers; Clinical Decision-Making; Clinical Trials as Topic; Comorbidity; Disease Management; Health Planning; Health Policy; Humans; Medical Informatics; Practice Guidelines as Topic; Reproducibility of Results; Rhinitis Allergic; Web Browser; Immunology and Allergy; ImmunologyInformation and communications technologyClinical decision support systemMACVIA-LRQuality of life (healthcare)AllergicARIA; Information and communications technology; MACVIA-LR; allergic rhinitis; asthmaJournal ArticleHumansCiências Médicas::Medicina ClínicaAsthmaScience & Technologyallergic rhinitisARIAbusiness.industrySettore MED/09 - MEDICINA INTERNAReproducibility of ResultsGuidelineBiomarkerta3121Allergensasthmamedicine.diseaseRhinitis AllergicIntegrated careHealth PlanningPOLLEN COUNTSICTallergic rhinitis; ARIA; asthma; Information and communications technology; MACVIA-LR; Allergens; Biomarkers; Clinical Decision-Making; Clinical Trials as Topic; Comorbidity; Disease Management; Health Planning; Health Policy; Humans; Medical Informatics; Practice Guidelines as Topic; Reproducibility of Results; Rhinitis Allergic; Web BrowserImmunologybusinessDECISION-SUPPORT-SYSTEMSBiomarkersMedical Informatics[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic…

2020

AbstractThe COVID-19 pandemic has surprised the entire population. The world has had to face an unprecedented pandemic. Only, Spanish flu had similar disastrous consequences. As a result, drastic measures (lockdown) have been adopted worldwide. Healthcare service has been overwhelmed by the extraordinary influx of patients, often requiring high intensity of care. Mortality has been associated with severe comorbidities, including chronic diseases. Patients with frailty were, therefore, the victim of the SARS-COV-2 infection. Allergy and asthma are the most prevalent chronic disorders in children and adolescents, so they need careful attention and, if necessary, an adaptation of their regular…

AllergyReview030207 dermatology & venereal diseasesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineCOVID-19 ; Child ; Pandemic ; Allergy ; Immunologic disease ; Asthma ; AdolescentPandemicViral030212 general & internal medicineDisease management (health)ChildSocieties MedicalCOVID-19; pandemic; child; adolescent; allergy; asthma; immunologic diseaseIncidence (epidemiology)lcsh:RJ1-570Disease ManagementGeneral MedicineAtopic dermatitisSettore MED/38Adolescent; Allergy; Asthma; Child; COVID-19; Immunologic disease; Pandemic; Adolescent; COVID-19; Child; Coronavirus Infections; Decision Making; Humans; Italy; Pneumonia Viral; Pragmatic Clinical Trials as Topic; SARS-CoV-2; Allergy and Immunology; Betacoronavirus; Consensus; Disease Management; Pandemics; Societies MedicalItalyLatex allergyAdolescent; Allergy; Asthma; COVID-19; Child; Immunologic disease; PandemicCoronavirus InfectionsHumanTelemedicineConsensusAdolescentDecision MakingPneumonia ViralConsensuBetacoronavirus03 medical and health sciencesMedicalAllergy and ImmunologyPragmatic Clinical Trials as TopicmedicineHumansRisk factorPandemicsPandemicBetacoronavirubusiness.industryCoronavirus InfectionSARS-CoV-2COVID-19lcsh:PediatricsPneumoniamedicine.diseaseAsthmaAdolescent; Allergy; Asthma; Child; COVID-19; Immunologic disease; PandemicImmunologic diseaseImmunologySocietiesbusinessRare disease
researchProduct

Aminobisphosphonate-activated γδ T cells in immunotherapy of cancer: doubts no more

2008

BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic …

Aminobisphosphonate Gamma delta T cells cancermedicine.medical_treatmentT cellClinical BiochemistryReceptors Antigen T-CellAntineoplastic AgentsModels BiologicalInterleukin 21Immune systemAntigenT-Lymphocyte SubsetsIn vivoNeoplasmsDrug DiscoveryAnimalsHumansCytotoxic T cellMedicinePharmacologyClinical Trials as TopicDiphosphonatesbusiness.industryT-cell receptorReceptors Antigen T-Cell gamma-deltaImmunotherapyKiller Cells Naturalmedicine.anatomical_structureImmune SystemImmunologyInterleukin-2ImmunotherapybusinessImmunologic MemoryExpert Opinion on Biological Therapy
researchProduct

Role of ARBs in the blood hypertension therapy and prevention of cardiovascular events

2009

Hypertension has a worldwide high incidence in the general population and undoubtedly it is the most important risk factor for cardiovascular morbidity and mortality, in industrialized countries. In this Review we investigated the role of angiotensin II receptor antagonists (ARBs) therapy in the treatment of essential hypertension. We selected in the PubMed and in a list of selected sources the most significant clinical trials and meta-analysis carried out from 1999 to now, to assess, in adult patients populations, ARBs efficacy, safety and tolerability profile, in comparison with the efficacy of the other common antihypertensive drugs, with particular regard to both the prevention of disab…

Angiotensin receptormedicine.medical_specialtyHeart DiseasesCost-Benefit AnalysisClinical BiochemistryPopulationPeptidyl-Dipeptidase AEssential hypertensionAngiotensin Receptor AntagonistsInternal medicineDrug DiscoverymedicineHumansRisk factoreducationAntihypertensive AgentsPharmacologyeducation.field_of_studyClinical Trials as TopicAngiotensin Receptor Antagonistsbusiness.industrymedicine.diseaseClinical trialCerebrovascular DisordersTreatment OutcomeTolerabilityARB blood hypertension cardiovascular eventsHeart failureHypertensionCardiologyMolecular Medicinebusiness
researchProduct

In vitro antifungal properties of mouthrinses containing antimicrobial agents

1997

The purpose of this study was to investigate the in vitro antifungal properties of seven commercial mouthrinses containing antimicrobial agents. These included cetylpyridinium chloride (CPC), chlorhexidine digluconate (CHX), hexetidine (HEX), sanguinarine (SNG), and triclosan (TRN). The minimum fungicidal concentration (MFC) against six species of yeasts was determined by a broth macrodilution method. The kill-time of mouthrinses at half the concentration of the commercial formulations was also determined. MFCs were achieved with each mouthrinse, except the SNG-containing mouthrinse, against all the organisms being tested. However, the CPC-containing mouthrinse appeared more active than the…

AntifungalTime FactorsAntifungal Agentsmedicine.drug_classColony Count MicrobialMouthwashesCetylpyridiniumSaccharomyces cerevisiaeHexetidineCetylpyridinium chlorideMicrobiologychemistry.chemical_compoundAlkaloidsCandidiasis OralCandida albicansmedicineHumansSanguinarineMinimum fungicidal concentrationFood scienceHexetidine/therapeutic useFungal diseases/prevention and controlCandidaBenzophenanthridinesClinical Trials as TopicChlorhexidineSanguinarine/therapeutic useFungiHexetidineIsoquinolinesAntimicrobialTriclosan/therapeutic useTriclosanIn vitroTriclosanchemistryEvaluation Studies as TopicCetylpyridinium chloride/therapeutic useChlorhexidine/therapeutic useAnti-Infective Agents LocalPeriodonticsMouthrinses/therapeutic use
researchProduct

Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials

2021

Medicinal mushrooms have important health benefits and exhibit a broad spectrum of pharmacological activities, including antiallergic, antibacterial, antifungal, anti-inflammatory, antioxidative, antiviral, cytotoxic, immunomodulating, antidepressive, antihyperlipidemic, antidiabetic, digestive, hepatoprotective, neuroprotective, nephroprotective, osteoprotective, and hypotensive activities. The growing interest in mycotherapy requires a strong commitment from the scientific community to expand clinical trials and to propose supplements of safe origin and genetic purity. Bioactive compounds of selected medicinal mushrooms and their effects and mechanisms in in vitro and in vivo clinical stu…

Antifungalin vitro studymedicine.drug_classpharmaceutical propertieantitumor propertyChemistry PharmaceuticalReviewHealth benefitsimmunomodulationbiomoleculesCatalysislcsh:Chemistrydietary supplementsInorganic ChemistryBroad spectrumIn vivomedicineAnimalsHumansIn vitro studyPhysical and Theoretical Chemistrylcsh:QH301-705.5mycotherapyMolecular BiologySpectroscopyClinical Trials as TopicTraditional medicinemedicinal mushroomsbusiness.industrySettore BIO/02 - Botanica SistematicaOrganic Chemistryclinical trialGeneral Medicinebiomoleculemedicinal mushroomComputer Science ApplicationsClinical triallcsh:Biology (General)lcsh:QD1-999dietary supplementSettore BIO/03 - Botanica Ambientale E Applicatapharmaceutical propertiesAgaricalesbusinessInternational Journal of Molecular Sciences
researchProduct

Succinobucol’s New Coat — Conjugation with Steroids to Alter Its Drug Effect and Bioavailability

2011

Synthesis, detailed structural characterization (X-ray, NMR, MS, IR, elemental analysis), and studies of toxicity, antioxidant activity and bioavailability of unique potent anti-atherosclerotic succinobucol-steroid conjugates are reported. The conjugates consist of, on one side, the therapeutically important drug succinobucol ([4-{2,6-di-tert-butyl-4-[(1-{[3-tert-butyl-4-hydroxy-5-(propan-2-yl)phenyl]sulfanyl}ethyl)sulfanyl]phenoxy}-4-oxo-butanoic acid]) possessing an antioxidant and anti-inflammatory activity, and on the other side, plant stanol/sterols (stigmastanol, β-sitosterol and stigmasterol) possessing an ability to lower the blood cholesterol level. A cholesterol-succinobucol prodr…

AntioxidantFree RadicalsStereochemistrymedicine.medical_treatmentStatic ElectricityAnti-Inflammatory AgentsBiological AvailabilityPharmaceutical ScienceprobucolArticleAntioxidantsAnalytical Chemistrylcsh:QD241-441Micechemistry.chemical_compoundPicrateslcsh:Organic chemistrySulfanylDrug DiscoverymedicineAnimalsHumansPhysical and Theoretical Chemistrysuccinobucol; phytosterol; atherosclerosis; cholesterol; probucolta317phytosterolStigmastanolClinical Trials as TopicMice Inbred BALB CMolecular StructurePhytosterolBiphenyl CompoundsOrganic Chemistrycholesterol3T3 CellsFibroblastsProdrugAscorbic acidBioavailabilityBiphenyl compoundchemistryChemistry (miscellaneous)Molecular MedicineSteroidsatherosclerosissuccinobucolMolecules; Volume 16; Issue 11; Pages: 9404-9420
researchProduct

Free radical biology of the cardiovascular system

2012

Most cardiovascular diseases (CVDs), as well as age-related cardiovascular alterations, are accompanied by increases in oxidative stress, usually due to increased generation and/or decreased metabolism of ROS (reactive oxygen species; for example superoxide radicals) and RNS (reactive nitrogen species; for example peroxynitrite). The superoxide anion is generated by several enzymatic reactions, including a variety of NADPH oxidases and uncoupled eNOS (endothelial NO synthase). To relieve the burden caused by this generation of free radicals, which also occurs as part of normal physiological processes, such as mitochondrial respiratory chain activity, mammalian systems have developed endogen…

AntioxidantFree Radicalsmedicine.medical_treatmentmedicine.disease_causeCardiovascular SystemAntioxidantsRenin-Angiotensin Systemchemistry.chemical_compoundmedicineAnimalsHumansReactive nitrogen speciesFree-radical theory of agingchemistry.chemical_classificationClinical Trials as TopicReactive oxygen speciesChemistrySuperoxideFree Radical ScavengersGeneral MedicinePPAR gammaOxidative StressMitochondrial respiratory chainBiochemistryCardiovascular DiseasesPeroxynitriteOxidative stressClinical Science
researchProduct

Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases.

2013

Resveratrol-a natural polyphenolic compound-was first discovered in the 1940s. Although initially used for cancer therapy, it has shown beneficial effects against most cardiovascular and cerebrovascular diseases. A large part of these effects are related to its antioxidant properties. Here we review: (a) the sources, the metabolism, and the bioavailability of resveratrol; (b) the ability of resveratrol to modulate redox signalling and to interact with multiple molecular targets of diverse intracellular pathways; (c) its protective effects against oxidative damage in cardio-cerebro-vascular districts and metabolic disorders such as diabetes; and (d) the evidence for its efficacy and toxicity…

Antioxidantmedicine.medical_treatmentBiological AvailabilityPharmacologyResveratrolBiologyToxicologymedicine.disease_causeAntioxidantsNitric oxidechemistry.chemical_compoundMetabolic DiseasesDiabetes mellitusStilbenesOxidative stress antioxidant brain cardiovascular diabetes nitric oxideDiabetes MellitusmedicineHumansClinical Trials as Topicfood and beveragesGeneral Medicinemedicine.diseaseBioavailabilityCerebrovascular DisordersOxidative StresschemistryCardiovascular DiseasesResveratrolToxicityOxidation-ReductionOxidative stressIntracellularFood Science
researchProduct